Drospirenone / ethinyl estradiol

All selected products prevent pregnancy in females of reproductive potential. Yaz and Vestura additionally treat PMDD symptoms in patients choosing oral contraception; efficacy beyond three menstrual cycles was not evaluated and PMS treatment is not established. They also treat moderate acne in patients age 14 or older after menarche who desire oral contraception and have no contraindication. Yasmin’s selected label indicates contraception, not these additional uses.

CDC 2024 classifies migraine with aura as unacceptable-risk CHC use. Obesity alone is generally category 2, while multiple thrombotic risks can change eligibility. Controlled hypertension, systolic 140–159 or diastolic 90–99 mmHg is generally category 3; systolic ≥ 160 or diastolic ≥ 100 mmHg, or vascular disease, is category 4. Drospirenone’s product-specific renal/adrenal restrictions still apply. Drospirenone-only, estetrol combinations and levomefolate-containing Beyaz/Safyral are outside this two-ingredient profile.

Each active pill contains drospirenone 3 mg. Take at the same time daily, with or without meals; start the next pack immediately after the last inactive tablet, without extra pill-free days.

Selected labels offer Day 1 or Sunday starts and require seven days of nonhormonal backup for a Sunday start or a start later than Day 1. Their nonbreastfeeding postpartum/second-trimester-abortion instructions start no earlier than four weeks. Switching from another pill starts when its next pack would be due; ring/patch/injection timing follows the next scheduled application/dose. Implant/IUD removal requires an individualized pregnancy-risk and backup plan. CDC 2024 permits quick-start when pregnancy is reasonably excluded and uses a five-day menstrual threshold for backup; retain a single clinician-selected start protocol rather than mixing instructions.

The following uses CDC 2024 SPR, distinguished from the labels’ current week-based missed-pill tables. For one late/missed active pill with < 48 hours elapsed, take it promptly and continue; backup is unnecessary. For ≥ 2 missed active pills (≥ 48 hours), take only the most recent missed pill, continue, and use condoms or abstain until seven consecutive active-pill days. If this occurs in the last active-pill week, skip the inactive interval. Discuss emergency contraception for first-week misses with unprotected intercourse in the previous five days; ulipristal requires separate restart advice.

Pack labels treat vomiting within 3–4 hours as a missed tablet. Current CDC guidance generally does not require redosing or backup for illness lasting < 48 hours; at ≥ 48 hours use backup until seven active-pill days after resolution, with last-week interval and emergency-contraception assessment as for missed pills. Missed inactive pills may be discarded; keep the next pack on time. Obtain a clear clinician plan when gastrointestinal illness or emergency contraception changes the schedule.

Do not use with renal impairment, adrenal insufficiency, liver disease or liver tumors, undiagnosed abnormal uterine bleeding, or current/past breast cancer. High arterial/venous thrombotic risk includes current/past DVT or PE, cerebrovascular/coronary disease, thrombogenic valve/rhythm disease, hypercoagulopathy, uncontrolled hypertension, diabetes with vascular disease, smoking over 35, focal neurologic headache, or migraine with/without aura over 35. CDC additionally treats migraine aura at any age as category 4. Concomitant ombitasvir plus paritaprevir/ritonavir, with or without dasabuvir, is contraindicated because of ALT elevation.

• Pregnancy is a reason to discontinue; do not misclassify it as a listed formal contraindication in every updated selected label.

Selected labels carry the cigarette-smoking/serious cardiovascular-events boxed warning. Risk increases with age and cigarette exposure; patients over 35 who smoke should not use these products. CDC smoking classifications begin at age 35 and distinguish cigarette quantity; this does not relax the product warning or replace individualized eligibility review.

Headache/migraine, irregular bleeding, nausea/vomiting, breast discomfort and mood changes are commonly reported; PMDD and contraception/acne trials have different adverse-event rates and should not be pooled. Serious events include thrombosis/stroke, liver problems, hypertension, hyperkalemia and hypersensitivity. Overdose can cause nausea or withdrawal bleeding; seek poison-center/clinical advice and assess potassium, sodium and metabolic acidosis as described in the label.

Reconcile all prescription drugs, supplements and OTC medicines before starting or stopping co-treatment.

Discontinue when pregnancy is recognized; there is no contraceptive indication during pregnancy. Epidemiologic early inadvertent exposure data have not shown an increased major-malformation risk, but this is not an indication to continue. Drospirenone reaches milk and CHCs can reduce production; selected labels advise other methods until breastfeeding ends when feasible. Consider breastfeeding benefits, maternal need and infant effects.

Selected pack labels require at least four weeks after delivery for nonbreastfeeding initiation. CDC prohibits CHCs before 21 postpartum days and applies breastfeeding/VTE-risk restrictions through 42 days; product timing and individual risk still matter. Do not assume a four-week date makes every postpartum patient eligible.

Contraceptive efficacy is expected to be similar in postpubertal adolescents and adults; use before menarche is not indicated. Yaz/Vestura acne use additionally requires age 14 or older and desire for contraception. Products are not indicated after menopause. Review smoking, migraine and vascular risks rather than using age alone as a universal eligibility rule.

Renal impairment and adrenal insufficiency are contraindications because of hyperkalemia vulnerability; do not infer permission from pharmacokinetic observations in mild impairment. Hepatic disease is contraindicated; moderate impairment increases drospirenone exposure about threefold, and severe disease was unstudied. These products have no approved organ-adjusted regimen that bypasses those restrictions.

COCs prevent pregnancy primarily by suppressing ovulation, with cervical-mucus and endometrial effects. Drospirenone has antiandrogenic and antimineralocorticoid activity; the exact contribution of those actions to acne response is unestablished. This combination is not an emergency contraceptive regimen.

Peak drospirenone/EE levels generally occur within 1–2 hours. Drospirenone’s terminal half-life is about 30 hours and EE’s about 24 hours; both are extensively metabolized, with urinary and fecal elimination of metabolites. EE undergoes first-pass metabolism and enterohepatic circulation. Drospirenone binds serum proteins strongly and oxidative metabolism includes CYP3A4. The single-ingredient bioavailability measurements should not be represented as directly measured absolute bioavailability of every combination pack.

Check BP before initiation and periodically; selected labels advise a yearly visit. Review new migraine/aura, smoking, vascular risks, intercurrent surgery, adherence and interacting medicines. Check first-cycle potassium with relevant chronic drugs; consider additional monitoring with high-risk chronic CYP3A4 inhibitor use. Evaluate persistent/new bleeding or absent periods according to adherence and pregnancy risk. Monitor diabetes, severe depression and lipid-related pancreatitis risk as appropriate.

Take the correct active/inactive sequence and arrange refills before the next pack. COCs do not prevent HIV or other sexually transmitted infections. Seek urgent help for chest pain, sudden breathlessness, unilateral leg pain/swelling, neurologic deficits, severe headache or visual loss. Report jaundice, severe mood change, unexplained bleeding or pregnancy concern. Tell clinicians about surgery, all medicines and supplements; ask for a written start/missed-pill plan rather than combining different protocols.

Yaz blister: 24 light-pink active round tablets embossed DS in a hexagon and 4 white inactive tablets embossed DP; selected three-blister package NDC 50419-405-03. Package identity is an example, not evidence of current stock.

Yaz/Vestura active tablets contain drospirenone 3 mg and EE 0.02 mg (20 mcg), with 24 active and 4 inactive per pack. Yasmin contains 3 mg and EE 0.03 mg (30 mcg), with 21 active and 7 inactive. Do not substitute a drospirenone-only 4 mg pack or a combination containing estetrol/levomefolate based on a shared ingredient name.

Yaz and Yasmin specify 25°C; Vestura specifies 20–25°C. All permit excursions 15–30°C. Keep the blister order intact and medicine away from children; follow the exact dispensed product’s package directions.